|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PSMC3 |
Gene summary for PSMC3 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PSMC3 | Gene ID | 5702 |
| Gene name | proteasome 26S subunit, ATPase 3 | |
| Gene Alias | DCIDP | |
| Cytomap | 11p11.2 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | A0A140VK42 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 5702 | PSMC3 | GSM4909281 | Human | Breast | IDC | 4.96e-02 | 2.22e-01 | 0.21 |
| 5702 | PSMC3 | GSM4909288 | Human | Breast | IDC | 2.74e-02 | 1.35e-01 | 0.0988 |
| 5702 | PSMC3 | GSM4909296 | Human | Breast | IDC | 1.21e-05 | -2.65e-02 | 0.1524 |
| 5702 | PSMC3 | GSM4909297 | Human | Breast | IDC | 2.51e-09 | -7.98e-02 | 0.1517 |
| 5702 | PSMC3 | GSM4909311 | Human | Breast | IDC | 2.23e-22 | -2.06e-01 | 0.1534 |
| 5702 | PSMC3 | GSM4909312 | Human | Breast | IDC | 2.10e-09 | -8.23e-02 | 0.1552 |
| 5702 | PSMC3 | GSM4909319 | Human | Breast | IDC | 2.77e-27 | -1.52e-01 | 0.1563 |
| 5702 | PSMC3 | GSM4909320 | Human | Breast | IDC | 3.12e-02 | -1.96e-01 | 0.1575 |
| 5702 | PSMC3 | GSM4909321 | Human | Breast | IDC | 2.97e-08 | -3.14e-03 | 0.1559 |
| 5702 | PSMC3 | brca1 | Human | Breast | Precancer | 6.32e-26 | 6.42e-01 | -0.0338 |
| 5702 | PSMC3 | brca2 | Human | Breast | Precancer | 2.29e-18 | 5.20e-01 | -0.024 |
| 5702 | PSMC3 | brca3 | Human | Breast | Precancer | 1.56e-03 | 1.62e-01 | -0.0263 |
| 5702 | PSMC3 | NCCBC14 | Human | Breast | DCIS | 6.14e-05 | -9.03e-02 | 0.2021 |
| 5702 | PSMC3 | NCCBC2 | Human | Breast | DCIS | 6.02e-04 | -2.43e-01 | 0.1554 |
| 5702 | PSMC3 | NCCBC5 | Human | Breast | DCIS | 1.08e-11 | 1.35e-01 | 0.2046 |
| 5702 | PSMC3 | P1 | Human | Breast | IDC | 2.29e-13 | -1.43e-01 | 0.1527 |
| 5702 | PSMC3 | P2 | Human | Breast | IDC | 1.03e-03 | 2.19e-01 | 0.21 |
| 5702 | PSMC3 | DCIS2 | Human | Breast | DCIS | 1.44e-50 | 1.29e-01 | 0.0085 |
| 5702 | PSMC3 | HTA11_2487_2000001011 | Human | Colorectum | SER | 1.21e-11 | 2.34e-01 | -0.1808 |
| 5702 | PSMC3 | HTA11_1938_2000001011 | Human | Colorectum | AD | 5.88e-11 | 3.37e-01 | -0.0811 |
| Page: 1 2 3 4 5 6 7 8 9 10 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00160329 | Breast | Precancer | viral process | 58/1080 | 415/18723 | 3.42e-10 | 3.16e-08 | 58 |
| GO:00458629 | Breast | Precancer | positive regulation of proteolysis | 51/1080 | 372/18723 | 7.77e-09 | 5.70e-07 | 51 |
| GO:00444039 | Breast | Precancer | biological process involved in symbiotic interaction | 42/1080 | 290/18723 | 3.40e-08 | 2.11e-06 | 42 |
| GO:00104989 | Breast | Precancer | proteasomal protein catabolic process | 58/1080 | 490/18723 | 1.54e-07 | 8.05e-06 | 58 |
| GO:19033629 | Breast | Precancer | regulation of cellular protein catabolic process | 36/1080 | 255/18723 | 6.03e-07 | 2.55e-05 | 36 |
| GO:00421769 | Breast | Precancer | regulation of protein catabolic process | 47/1080 | 391/18723 | 1.50e-06 | 5.58e-05 | 47 |
| GO:19030509 | Breast | Precancer | regulation of proteolysis involved in cellular protein catabolic process | 31/1080 | 221/18723 | 4.10e-06 | 1.27e-04 | 31 |
| GO:00611369 | Breast | Precancer | regulation of proteasomal protein catabolic process | 24/1080 | 187/18723 | 1.99e-04 | 3.14e-03 | 24 |
| GO:00431619 | Breast | Precancer | proteasome-mediated ubiquitin-dependent protein catabolic process | 42/1080 | 412/18723 | 2.49e-04 | 3.72e-03 | 42 |
| GO:00098969 | Breast | Precancer | positive regulation of catabolic process | 48/1080 | 492/18723 | 2.62e-04 | 3.84e-03 | 48 |
| GO:00313319 | Breast | Precancer | positive regulation of cellular catabolic process | 43/1080 | 427/18723 | 2.75e-04 | 4.00e-03 | 43 |
| GO:19033649 | Breast | Precancer | positive regulation of cellular protein catabolic process | 20/1080 | 155/18723 | 6.10e-04 | 7.67e-03 | 20 |
| GO:19030527 | Breast | Precancer | positive regulation of proteolysis involved in cellular protein catabolic process | 17/1080 | 133/18723 | 1.68e-03 | 1.70e-02 | 17 |
| GO:00457329 | Breast | Precancer | positive regulation of protein catabolic process | 25/1080 | 231/18723 | 1.87e-03 | 1.82e-02 | 25 |
| GO:19018007 | Breast | Precancer | positive regulation of proteasomal protein catabolic process | 15/1080 | 114/18723 | 2.31e-03 | 2.15e-02 | 15 |
| GO:001603214 | Breast | IDC | viral process | 75/1434 | 415/18723 | 1.98e-12 | 4.02e-10 | 75 |
| GO:004586214 | Breast | IDC | positive regulation of proteolysis | 66/1434 | 372/18723 | 9.76e-11 | 1.29e-08 | 66 |
| GO:001049814 | Breast | IDC | proteasomal protein catabolic process | 75/1434 | 490/18723 | 5.59e-09 | 4.41e-07 | 75 |
| GO:004440314 | Breast | IDC | biological process involved in symbiotic interaction | 52/1434 | 290/18723 | 6.55e-09 | 5.03e-07 | 52 |
| GO:004217614 | Breast | IDC | regulation of protein catabolic process | 63/1434 | 391/18723 | 1.32e-08 | 9.61e-07 | 63 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0501218 | Breast | Precancer | Parkinson disease | 99/684 | 266/8465 | 3.58e-42 | 5.65e-40 | 4.33e-40 | 99 |
| hsa0502016 | Breast | Precancer | Prion disease | 95/684 | 273/8465 | 1.39e-37 | 1.46e-35 | 1.12e-35 | 95 |
| hsa0501616 | Breast | Precancer | Huntington disease | 98/684 | 306/8465 | 2.85e-35 | 2.25e-33 | 1.72e-33 | 98 |
| hsa0501016 | Breast | Precancer | Alzheimer disease | 103/684 | 384/8465 | 1.03e-29 | 4.66e-28 | 3.57e-28 | 103 |
| hsa0501416 | Breast | Precancer | Amyotrophic lateral sclerosis | 98/684 | 364/8465 | 2.13e-28 | 8.41e-27 | 6.44e-27 | 98 |
| hsa0502216 | Breast | Precancer | Pathways of neurodegeneration - multiple diseases | 112/684 | 476/8465 | 6.96e-27 | 2.44e-25 | 1.87e-25 | 112 |
| hsa0305010 | Breast | Precancer | Proteasome | 25/684 | 46/8465 | 4.35e-16 | 9.81e-15 | 7.52e-15 | 25 |
| hsa0501714 | Breast | Precancer | Spinocerebellar ataxia | 29/684 | 143/8465 | 2.79e-06 | 3.83e-05 | 2.94e-05 | 29 |
| hsa0516918 | Breast | Precancer | Epstein-Barr virus infection | 35/684 | 202/8465 | 1.15e-05 | 1.26e-04 | 9.64e-05 | 35 |
| hsa0501219 | Breast | Precancer | Parkinson disease | 99/684 | 266/8465 | 3.58e-42 | 5.65e-40 | 4.33e-40 | 99 |
| hsa0502017 | Breast | Precancer | Prion disease | 95/684 | 273/8465 | 1.39e-37 | 1.46e-35 | 1.12e-35 | 95 |
| hsa0501617 | Breast | Precancer | Huntington disease | 98/684 | 306/8465 | 2.85e-35 | 2.25e-33 | 1.72e-33 | 98 |
| hsa0501017 | Breast | Precancer | Alzheimer disease | 103/684 | 384/8465 | 1.03e-29 | 4.66e-28 | 3.57e-28 | 103 |
| hsa0501417 | Breast | Precancer | Amyotrophic lateral sclerosis | 98/684 | 364/8465 | 2.13e-28 | 8.41e-27 | 6.44e-27 | 98 |
| hsa0502217 | Breast | Precancer | Pathways of neurodegeneration - multiple diseases | 112/684 | 476/8465 | 6.96e-27 | 2.44e-25 | 1.87e-25 | 112 |
| hsa0305013 | Breast | Precancer | Proteasome | 25/684 | 46/8465 | 4.35e-16 | 9.81e-15 | 7.52e-15 | 25 |
| hsa0501715 | Breast | Precancer | Spinocerebellar ataxia | 29/684 | 143/8465 | 2.79e-06 | 3.83e-05 | 2.94e-05 | 29 |
| hsa0516919 | Breast | Precancer | Epstein-Barr virus infection | 35/684 | 202/8465 | 1.15e-05 | 1.26e-04 | 9.64e-05 | 35 |
| hsa0501224 | Breast | IDC | Parkinson disease | 107/867 | 266/8465 | 2.57e-39 | 8.36e-37 | 6.26e-37 | 107 |
| hsa0502023 | Breast | IDC | Prion disease | 102/867 | 273/8465 | 3.70e-34 | 4.01e-32 | 3.00e-32 | 102 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PSMC3 | SNV | Missense_Mutation | novel | c.427N>C | p.Glu143Gln | p.E143Q | P17980 | protein_coding | tolerated(0.11) | benign(0.157) | TCGA-A2-A4RW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| PSMC3 | SNV | Missense_Mutation | c.149N>A | p.Ser50Asn | p.S50N | P17980 | protein_coding | tolerated(1) | benign(0.001) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| PSMC3 | SNV | Missense_Mutation | c.874N>A | p.Gly292Ser | p.G292S | P17980 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-C8-A1HE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| PSMC3 | SNV | Missense_Mutation | c.73N>A | p.Glu25Lys | p.E25K | P17980 | protein_coding | tolerated(0.12) | benign(0.003) | TCGA-EW-A1J5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| PSMC3 | SNV | Missense_Mutation | novel | c.532N>C | p.Asp178His | p.D178H | P17980 | protein_coding | deleterious(0.02) | probably_damaging(0.97) | TCGA-C5-A1MH-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | PD |
| PSMC3 | SNV | Missense_Mutation | c.73N>A | p.Glu25Lys | p.E25K | P17980 | protein_coding | tolerated(0.12) | benign(0.003) | TCGA-DG-A2KM-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | |
| PSMC3 | SNV | Missense_Mutation | rs771618920 | c.329A>G | p.Asn110Ser | p.N110S | P17980 | protein_coding | tolerated(0.2) | benign(0) | TCGA-A6-3810-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| PSMC3 | SNV | Missense_Mutation | c.380N>T | p.Ser127Phe | p.S127F | P17980 | protein_coding | deleterious(0) | possibly_damaging(0.868) | TCGA-AA-3713-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | 5-fluorouracil | PR | |
| PSMC3 | SNV | Missense_Mutation | novel | c.375N>C | p.Lys125Asn | p.K125N | P17980 | protein_coding | deleterious(0.04) | possibly_damaging(0.535) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| PSMC3 | SNV | Missense_Mutation | c.1178N>A | p.Gly393Glu | p.G393E | P17980 | protein_coding | deleterious(0) | probably_damaging(0.943) | TCGA-AA-A01D-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | capecitabine | PD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 5702 | PSMC3 | NA | inhibitor | BORTEZOMIB | BORTEZOMIB | |
| 5702 | PSMC3 | NA | inhibitor | CARFILZOMIB | CARFILZOMIB | |
| 5702 | PSMC3 | NA | inhibitor | CHEMBL2103884 | OPROZOMIB | |
| 5702 | PSMC3 | NA | inhibitor | CHEMBL451887 | CARFILZOMIB | |
| 5702 | PSMC3 | NA | BORTEZOMIB | BORTEZOMIB | 24524217 | |
| 5702 | PSMC3 | NA | inhibitor | CHEMBL325041 | BORTEZOMIB | |
| 5702 | PSMC3 | NA | CARFILZOMIB | CARFILZOMIB | 24524217 | |
| 5702 | PSMC3 | NA | inhibitor | CHEMBL3545432 | IXAZOMIB CITRATE |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |